BioAtla, Inc. 10-Q

Item 5 . Other Information. During the three months ended June 30, 2026 , no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K. First Amendment to EXUMA License Agreement On August 12, 2026 (the “Effective Date”), we entered into the First Amendment (the “First Amendment”) to the Amended and Restated Exclusive License Agreement, dated November 22, 2019 (the “EXUMA License Agreement”), with EXUMA Biotech Corp. (formerly F1 Oncology, Inc.), a Delaware corporation (“EXUMA”), covering certain CAR-T therapies. Under the terms of the First Amendment, and in full consideration for the license and other rights granted by the Company under the EXUMA License Agreement, EXUMA has agreed to pay us $250,000 in immediately available funds within two (2) business days of the Effective Date (the “Amendment Pay-Off Amount”). The Amendment Pay-Off Amount satisfies in full any and all royalty payment obligations contemplated by the EXUMA License Agreement. Under the terms of the First Amendment, the exclusive license granted to EXUMA under the EXUMA License Agreement is amended to be royalty-free, fully paid-up, irrevocable, perpetual and non-terminable, and EXUMA shall be responsible for all Joint Patent (as defined in the EXUMA License Agreement) costs, whether currently outstanding or due in the future. The above description of the First Amendment is qualified in its entirety by reference to the full text of the First Amendment, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. 80 Item 6 . Exhibits. Exhibit Number Description Form File No. Exhibit Exhibit Filing Date File/Furnished Herewith 10.1* First Amendment to the License Agreement between BioAtla, Inc. and Context Therapeutics Inc., dated as of May 14, 2026 10-Q 001-39787 10.3 05-15-2026 31.1 Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 31.2 Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 32.1† Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 99.1 Amendment No. 1 to Agreement and Plan of Merger, dated as of March 2, 2026, by and between BioAtla, Inc. and BA Merger Sub, Inc. 8-K 001-39787 1.1 03-02-2026 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. X 101 The following materials from BioAtla’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, formatted in iXBRL (inline eXtensible Business Reporting Language): (i) the Condensed Balance Sheets, (ii) the Condensed Statements of Operations and Comprehensive Income (Loss), (iii) the Condensed Statements of Stockholders’ Equity (Deficit), (iv) the Condensed Statements of Cash Flows, and (v) Notes to Condensed Financial Statements, tagged as blocks of text and including detailed tags. X 104 Cover Page Interactive Data File (formatted as Inline XBRL document and contained in exhibit 101). X † Furnished and not filed. * Portions of this exhibit have been omitted or redacted in accordance with Item 601(a)(5) or Item 601(b)(10)(iv) of Regulation S-K. 81 SIG NATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioAtla, Inc. Date: August 13, 2026 By: /s/ Jay M. Short, Ph.D. Jay M. Short, Ph.D. Chief Executive Officer (Principal Executive Officer) Date: August 13, 2026 By: /s/ Christian Vasquez Christian Vasquez Chief Financial Officer (Principal Financial and Accounting Officer) 82